CANbridge Granted China Priority Review for Rare Disease Treatment

CANbridge
Published on: September 11, 2019
Author: Amy Liu

CANbridge Pharma of Shanghai announced China granted Priority Review status to Hunterase (idursulfate beta) to treat a rare disease, Hunter syndrome (mucopolysaccharidosis type II). Hunter syndrome is a rare, disabling, life-threatening genetic disease, which has a higher prevalence in Asia than elsewhere in the world. Developed by Korea’s GC Pharma, Hunterase is approved to treat Hunter syndrome in 10 countries. CANbridge in-licensed China rights to Hunterase from GC Pharma earlier this year, and filed a China NDA for the enzyme replacement in July. CANbridge specializes in China treatments for rare diseases and targeted cancer drugs. Source: China Biotoday  

Biotechnology Healthcare Healthcare Services Life Science Pharmaceutical